Immunovant (IMVT) Shares Outstanding (2018 - 2026)

Immunovant (IMVT) has 9 years of Shares Outstanding (Entity) data on file, last reported at $203.9 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 19.89% year-over-year to $203.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $203.9 million (up 19.89% YoY) and the FY2026 annual result came in at $203.9 million, up 19.89% from the prior year.
• Shares Outstanding (Entity) steadied at $203.9 million in Q1 2026, from $203.3 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $203.9 million in Q1 2026 to a low of $116.5 million in Q1 2022.
• A 5-year average of $148.5 million and a median of $145.6 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) rose 1.4% — and 2025, when it surged 38.12%.
• Tracing IMVT's Shares Outstanding (Entity) over 5 years: stood at $129.3 million in 2022, then rose by 12.25% to $145.1 million in 2023, then climbed by 1.45% to $147.2 million in 2024, then surged by 38.12% to $203.3 million in 2025, then rose by 0.31% to $203.9 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $203.9 million (Q1 2026), $203.3 million (Q4 2025), and $174.5 million (Q3 2025), per Business Quant data.